Unternehmens-Profil
Fresenius SE & Co. KGaA is a global healthcare group founded in 1912 and headquartered in Bad Homburg, Germany. It specializes in providing critical products and services for treating and caring for critically and chronically ill patients, focusing on therapies like dialysis, infusion, and clinical nutrition. The company operates through key segments including Fresenius Kabi, which supplies biopharmaceuticals, IV drugs, medical devices, and clinical nutrition; Fresenius Helios, Europe’s leading private hospital operator with facilities in Germany and Spain; and Fresenius Vamed, which manages healthcare facility projects from planning to operations. With approximately 176,000 employees and presence in over 60 countries across North America, Europe, Asia-Pacific, Latin America, and Africa, Fresenius generates substantial revenue—around €21.5-23.3 billion in recent years—through an international distribution network and over 50 production sites. Its mission emphasizes affordable, accessible, innovative solutions and high-quality clinical care, positioning it as a leader in addressing global healthcare demands driven by aging populations and chronic conditions.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 40,74 EUR· Stand 07.05.2026
News · Fresenius SE & Co. KGaA
- Fresenius SE & Co. KGaA (FSNUY) Q1 2026 Earnings Call Transcript
- Fresenius SE & Co. KGaA (FSNUY) Q4 2025 Earnings Call Transcript
- Fresenius SE & Co. KGaA (FSNUY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Fresenius SE & Co. KGaA (FSNUY) Analyst/Investor Day Transcript
- Fresenius SE & Co. KGaA (FSNUY) Q3 2025 Earnings Call Transcript